Rapid advancements in nanotechnology have improved efficiency of microneedle patches through a shift from undissolving to dissolving microneedles. Microneedle patches can effectively deliver bioactive molecular of different physical size and hence are considered as robust drug delivery tools. Microneedle patches can also be coated or encapsulated with DNA vaccine, inactivated or live virus vaccine, and subunit antigen, among others. Microneedle patches have several advantages when used as drug and vaccine delivery vehicles such as pain-free and non-invasive route for reagent administration, no cold chain requirement for storage and transportation, low risk of needle-related injuries, and decrease in medical waste and transmission of blood-borne infectious diseases, particular in low-income and underdeveloped regions. Microneedle patches utilize the concept of microneedling to increase efficacy of active ingredients and use self-dissolving needles to penetrate the surface of the skin.
Microneedle patches, which are a highly efficient and
versatile devices, have garnered extensive scientific and industrial attention
over the past decade due to their attributes such as painless penetration, low
cost, relative safety, and tremendous therapeutic efficacy. On the research
front, microneedle patch has been used for minimally invasive evaluation of
levels of inflammatory biomarkers and for efficient sampling of clavarial
periosteum, which is a challenging site for biomarker detection, in mice. Use
of microneedle patches for minimally invasive collection and analysis of
biomarker levels in interstitial fluid has the potential to facilitate
point-of-care (PoC) diagnostics and longitudinal monitoring. Increasing role of
microneedles in revolutionizing the field of disease diagnosis and treatment,
cosmetic applications, and immunobiological administration can open up new
perspectives for development of advanced microneedles and contribute to revenue
growth of the micro needle market.
Browse Full Report
Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/micro-needle-patch-market
In a recent research study published in Immunotherapy,
researchers at Michigan Medicine partnered with Moonlight Therapeutics to
develop 1 cm x 1 cm arrays of 50 microneedles each which measure 700 μm and
each array is coated in formulation of peanut protein. The study was aimed at
determining the efficacy of peanut-coated microneedle patches in peanut allergy
while comparing the results of this approach with epicutaneous immunotherapy
with peanut. The researchers inserted these peanut-coated microneedles into the
hairless skin of female mice that were already sensitized to peanuts and held
them in place for nearly 5 minutes to enable dissolution of protein inside the
skin. The treatment was administered once a week for 5 weeks and results found
that 90% mice that received PN-MN treatment developed no allergic responses. Moonlight
Therapeutics in now planning first clinical trial of this approach in human
volunteers and researchers believe microneedle treatment can provide a new
frontier in enhancing cutaneous immunotherapy and improve administration of
next-generation therapeutics for treating peanut and other food allergies.
In a breakthrough scientific study, researchers found
that using 3D-printed microneedle
patches for drug delivery resulted in enhanced cargo retention on the skin,
robust activation of immune cells, and generation of more potent and cellular
immune responses as compared with conventional vaccination routes. Similarly, a
team of researchers and scientists from University of Queensland tested a
COVID-19 vaccine patch that is capable of delivering pain-free dosage and
eliminates the need for cold chain transport. The microneedle patch that can
deliver COVID-19 DNA vaccine into the skin was found to induce strong immune
responses in cells and mice. Researchers believe these advancements and
applications of microneedle patches can potentially replace syringes over the
coming years and is expected to drive market growth going ahead.
Prominent companies in the market include 3M Company,
Becton Dickinson and Company, Zosano Pharma Corporation, Raphas Co. Ltd.,
Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko
Corporation, Microdermics, Inc., Sanofi S.A. Recently, in April 2022, CGBIO,
which is a total healthcare provider based in Seoul, South Korea, acquired a
12.3% stake in Daewoong Therapeutics, which is a bio-venture company that has
developed a transdermal drug delivery system based on microneedle patches. The
former is trying to develop cosmetics, medical devices, and medicine using microneedle
technology and is expected to benefit from in-house technology of Daewoong
Therapeutics.
Custom Requirements
can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/993
No comments:
Post a Comment